Registry for Hemoperfusion of Covid-19 ICU Patients

Critical Illness Clinical Trial

— HERICC  

Official title:

South-Eastern Europe Registry for Hemoperfusion of Covid-19 ICU Patients

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05470907
• Other study ID #: HERICC-1982
• Status: Enrolling by invitation
• Start date: July 21, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: February 2024
• Source: Croatian Society for Organ Support
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The ongoing COVID-19 pandemic caused high hospitalization and mortality rates especially in critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. The purpose of this registry study is to investigate the effectiveness and safety of the extracorporeal blood purification and hemoperfusion/hemadsorption filters in treating of critically ill COVID-19 patients.

Description:

The COVID-19 pandemic has been associated with high mortality rate and high percentage of patients with with severe multi-organ dysfunction. Many therapies were investigated in this group of patients. The usage of extracorporeal blood purification, namely hemoperfusion/hemadsorption was introduced in everyday clinical practice even before COVID-19 pandemic in which became increasingly common. The efficacy of hemoperfusion/hemadsorption in removal of endotoxins and cytokines is still questioned by some physicians mostly due to the fact that some trials failed to demonstrate the effect of this therapy on long-term outcomes of critically ill patients. Unfortunately, there is no present study with a large number of patients that would offer us clear answers on the treatment of ICU COVID-19 patients with adsorption filters, extracorporeal methods and the hemoperfusion method. Several extracorporeal blood purification therapies have been proposed to attenuate systemic inflammation in COVID-19 patients but there is no study which analyzed more than one filter or patients without specific conditions. Due to these limitations the studies were not able to analyze the method itself. Therefore, the primary aim of this observational prospective, multi-centric, regional web-based registry is to define the results and outcome of treatment, possible advantages over patients who have not undergone targeted treatment and to set regional indications/inclusion criteria for the treatment of ICU COVID-19 patients with the method of hemoadsorption/hemoperfusion.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 300
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. COVID-19 infection

2. laboratory and clinical evidence of systemic inflammation: high levels of inflammatory cytokines such as IL-6 (>25 pg / ml); high values of inflammatory parameters from serum (leukocytes >15x10 9 / l, CRP >40 mg / l, procalcitonin >0.9 mg / l) and a high SOFA score (>2).

3. diagnosed with sepsis or septic shock: sepsis is defined as the presence of suspected or documented infections along with systemic inflammatory response syndrome; septic shock is defined as the presence of sepsis and acute circulatory failure according to European criteria Society for Intensive Care Medicine

4. clinical symptoms of hemodynamic instability requiring vasopressors and initial signs immune dysregulation or cascade coagulation disorders

5. acute kidney injury assessed according to KDIGO / AKIN criteria: increase in serum creatinine = 0.3 mg / dL within 48 hours, or = 50% over 7 days, or hourly diuresis <0.5 mL / kg / h for more than 6 hours

6. diagnosis of ARDS

7. the need for ECMO

8. deterioration of respiratory status with the onset of respiratory failure requiring mechanical ventilation (respiration rate >30 / min, or oxygen saturation <93%, or PaO2 / FiO2 ratio <300mmHg).

9. Admission to ICU

Exclusion Criteria:

• besides contraindications to the use of the hemoperfusion adopted (as from the manual of instructions), there are no exclusion criteria

Related Conditions & MeSH terms

• Acute Kidney Injury
• Acute Lung Injury
• COVID-19
• Critical Illness
• Multi Organ Failure
• Multiple Organ Failure
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome
• Systemic Inflammatory Response Syndrome
• Viral Disease
• Virus Diseases

Intervention

Device:
• Hemoperfusion
Commercial membranes for extracorporeal blood purification (hemoperfusion)

Locations

Country	Name	City	State
Croatia	University Hospital Center Zagreb	Zagreb	Grad Zagreb

Sponsors (2)

Lead Sponsor	Collaborator
Croatian Society for Organ Support	Clinical Hospital Centre Zagreb

Country where clinical trial is conducted

Croatia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Define the inclusion criteria for hemoperfusion in ICU COVID-19 patients	Define the inclusion criteria for extracorporeal blood purification (hemoperfusion) with different filters/hemadsorbers in ICU COVID-19 patients	28 days
Secondary	To assess the correlation between hemoperfusion and positive short-term outcome	Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	24 hours after hemoperfusion initiation
Secondary	To assess the correlation between hemoperfusion and positive short-term outcome	Define as to assess the correlation between hemoperfusion and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	72 hours after finishing all the hemoperfusion procedures
Secondary	To assess the correlation between hemoperfusion and positive long-term outcome	To assess the correlation between hemoperfusion and positive long-term outcome, defined as patient survival at ICU discharge.	28 days
Secondary	To assess the correlation between different filters/hemadsorbers and positive short-term outcome	Define as to assess the correlation between different filters/hemadsorbers and positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	24 hours after hemoperfusion initiation
Secondary	To assess the correlation between different filters/hemadsorbers and positive short-term outcome	Define as to assess the correlation between different filters/hemadsorbers and positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	72 hours after finishing all the hemoperfusion procedures
Secondary	To assess the correlation between different filters/hemadsorbers and positive long-term outcome	To assess the correlation between different filters/hemadsorbers and positive long-term outcome, defined as patient survival at ICU discharge.	28 days
Secondary	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	24 hours after initiation of the procedure with the combination of filters/hemadsorbers and extracorporeal organ support therapy
Secondary	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive short-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	72 hours after finishing all the procedures with the combination of filters/hemadsorbers and extracorporeal organ support therapy
Secondary	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome	The effects of filters/hemadsorbents in combination with other extracorporeal organ support therapies (i.e. ECMO, CRRT) on positive long-term outcome (i.e. an improvement in hemodynamic stability, inflammatory status and respiratory status).	28 days